Mingkun Yu | Cancer Cell Biology | Best Researcher Award

Dr. Mingkun Yu | Cancer Cell Biology | Best Researcher Award

Dr. Mingkun Yu , Binzhou Medical College Affiliated Traditional Chinese Medicine Hospital(Binzhou Traditional Chinese Medicine Hospital) , China

Dr. Mingkun Yu is an Associate Chief Physician at Binzhou Traditional Chinese Medicine Hospital, affiliated with Binzhou Medical College, China. He is an expert in integrating evidence-based medicine with traditional Chinese and Western medical practices, especially within oncology and ophthalmology. With over five years of clinical experience, Dr. Yu has made significant contributions to the field through impactful clinical research, trial designs, and methodological innovation. He is the recipient of a National Natural Science Foundation of China project and has led the development of national-level guidelines. Dr. Yu’s publications have gained high visibility, with citations and downloads from prestigious journals like BMJ. He collaborates with renowned experts worldwide and actively contributes as a peer reviewer for SCI journals. Known for his meticulous clinical approach and research rigor, Dr. Yu is a rising star in integrative medical science, particularly in addressing patient compliance and advancing myopia-related research strategies.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Academic Excellence
    Dr. Yu has earned advanced degrees from top-tier traditional Chinese medicine institutions in China, culminating in a PhD focused on integrated clinical medicine—a rare and interdisciplinary specialty.

  2. Proven Research Record

    • Published 7 SCI-indexed papers (including in BMJ and Therapeutic Advances in Gastroenterology) and 5 Chinese core journal papers.

    • First/corresponding author impact factor: 18.3; co-author cumulative impact factor: 112.

    • One article with 9248 downloads, another cited 66 times—demonstrating strong academic reach and relevance.

  3. Research Leadership

    • Designed and led multiple RCTs, cohort studies, and cluster RCTs.

    • Principal investigator of a National Natural Science Foundation of China project.

    • Spearheaded the national-level guideline on myopia—a major public health concern in Asia.

  4. Innovative Contributions

    • Introduced target value analysis and conducted extensive patient compliance research in clinical trials.

    • Integrated evidence-based methods with traditional Chinese medicine, a cutting-edge niche in global medical research.

  5. Collaborations & Peer Review

    • Collaborates with global leaders such as Paul Little, Gordon Guyatt, and Lehana Thabane.

    • Reviewer for top SCI journals including European Journal of Integrative Medicine and BMC Geriatrics.

⚙️ Areas for Improvement:

  1. Global Dissemination & Outreach

    • Dr. Yu could further enhance his profile by increasing international speaking engagements, attending more global medical symposia, and joining international research societies.

  2. Books or Monographs

    • No books published yet. Authoring clinical reference books or practitioner guides would boost both practical impact and professional visibility.

  3. Translational Research and Patents

    • With only one published patent, there is scope to convert more research findings into innovative tools, treatments, or technologies for broader clinical application.

  4. Professional Memberships

    • Active memberships in professional research or clinical bodies could enhance his professional network and visibility in award circuits.

📚 Education:

Dr. Yu earned his Master’s degree in Evidence-Based Medicine (Oncology) from Beijing University of Traditional Chinese Medicine in 2021. His academic journey culminated in a PhD in Clinical Medicine (Integrated Traditional Chinese and Western Medicine) from Shandong University of Traditional Chinese Medicine in 2024. Throughout his education, Dr. Yu focused on bridging the gap between traditional Chinese therapeutic principles and contemporary Western medical methodologies. His doctoral research emphasized designing clinical trials, evaluating treatment efficacy using systematic review and meta-analysis, and developing methodologies for improving patient outcomes. His educational background also provided him with comprehensive knowledge in oncology, ophthalmology, acupuncture, and behavioral health, preparing him to implement innovative, integrative solutions in clinical practice. He was mentored by leading figures in evidence-based medicine and engaged in collaborative studies with international researchers, further enriching his global research perspective.

🩺 Experience:

With more than 5 years of experience in clinical medicine, Dr. Mingkun Yu has become a prominent practitioner and researcher in integrated traditional Chinese and Western medical care. As an Associate Chief Physician at Binzhou Traditional Chinese Medicine Hospital, he leads and participates in high-level clinical research projects, including randomized controlled trials and cohort studies. He has contributed to over 7 national-level research projects and served as principal investigator in hospital-based clinical studies. Dr. Yu’s areas of expertise include patient compliance strategies in oncology, evidence synthesis in myopia prevention, and methodological development for clinical trials. He is a frequent presenter at national and international conferences and has served as a reviewer for SCI-indexed journals. Dr. Yu is also involved in writing clinical practice guidelines and has been recognized for his scientific contributions through research awards and publications in high-impact journals.

🔬 Research Focus:

Dr. Mingkun Yu’s research lies at the intersection of evidence-based medicine and integrated Chinese and Western clinical practices. His key focus areas include patient compliance in oncology, risk factor identification and prevention strategies for myopia, and designing robust clinical trials like RCTs, cohort, and cluster studies. He actively develops and applies systematic review methodologies, meta-analyses, and guideline development processes to ensure high-impact clinical outcomes. Dr. Yu has innovated in the area of patient compliance by applying qualitative synthesis and target value analysis, improving retention and adherence in clinical trials. He is particularly invested in the development of guidelines for myopia in children and adolescents and has published widely in SCI journals. His collaboration with global experts such as Paul Little, Gordon Guyatt, and Lehana Thabane strengthens the international relevance of his work. Through this multifaceted research approach, Dr. Yu aims to bridge traditional wisdom with modern scientific rigor.

📝 Publications Top Notes:

📄 Pseudomyopia as an independent risk factor for myopia onset: a prospective cohort study among school-aged childrenBritish Journal of Ophthalmology, 2024
📘 The Process factors and improvement strategies of patient compliance and retention in clinical trials: a synthesis of qualitative researchInplasy Report, 2021
📚 Berberine for diarrhea in children and adults: a systematic review and meta-analysisTherapeutic Advances in Gastroenterology, 2020

🧾 Conclusion:

Dr. Mingkun Yu stands out as a highly deserving candidate for the Best Researcher Award due to his cross-disciplinary research integrating traditional Chinese and Western medicine, his leadership in national clinical trials, impactful publications, and commitment to clinical innovation. His scholarly output is not only substantial but also highly cited and widely read, reflecting real-world influence and academic excellence.

With a growing international research presence, a unique focus on culturally integrated methodologies, and an impressive trajectory of innovation and collaboration, Dr. Yu clearly embodies the ideals of a next-generation clinical research leader.

Weifen Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Weifen Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Weifen Zhang , Shandong Second Medical University , China

Professor Weifen Zhang is a renowned scientist in pharmaceutical sciences, serving as a Professor at the School of Pharmacy, Shandong Second Medical University. She also directs the Shandong Engineering Research Center for Intelligent Materials and Regenerative Medicine and the Pharmaceutical Experimental Teaching Center. With over 50 SCI-indexed publications and 27 national and international patents, her contributions have significantly influenced the development of targeted drug delivery systems and smart biomaterials. A recipient of the State Council Special Allowance and recognized as a Shandong Provincial Outstanding Expert, Professor Zhang combines academic excellence with practical innovation. She has led and collaborated on numerous national-level research projects, focusing on novel therapeutic strategies for cancer, regenerative medicine, and nano-drug technologies. Additionally, she plays a prominent role in scientific publishing as a guest editor and reviewer for leading journals. Her dedication to interdisciplinary research continues to shape the future of pharmaceutical technology.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. 📚 High Research Productivity: Over 50 SCI-indexed publications in high-impact journals such as ACS Applied Materials & Interfaces, Journal of Biomedical Nanotechnology, and Science China Materials.

  2. 💡 Innovation & Intellectual Property: Holds 27 national and international patents, showing a strong translation of academic work into real-world applications.

  3. 🔬 Research Focus & Impact: Cutting-edge work in targeted drug delivery systems, intelligent biomaterials, and regenerative medicine, especially impactful in oncology.

  4. 🎯 Project Leadership: Principal Investigator for multiple nationally funded projects, managing significant funding amounts and driving original discoveries.

  5. 🌐 Academic Influence: Serves as a guest editor and reviewer for leading scientific journals, contributing to quality control and peer knowledge advancement.

  6. 📖 Educational Impact: Contributions to national-level textbooks like Pharmaceutics and Pharmaceutical English highlight her role in shaping future pharmaceutical education.

  7. 🤝 Industry Collaboration: Active collaborations with companies like NOIMAIER (Shandong) Medical Technology Co., Ltd, demonstrating practical application and outreach.

⚠️ Areas for Improvement:

  1. 🌍 Global Outreach: While her influence is strong nationally, increased participation in international conferences, collaborations, and global visibility would further elevate her stature.

  2. 🎙️ Public Engagement: Enhanced involvement in science communication, including talks, public articles, or media, could broaden her societal impact.

  3. 🌐 Online Presence: A more visible online research profile (e.g., Google Scholar, ResearchGate, LinkedIn) could help in networking and research dissemination globally.

🎓 Education:

Professor Weifen Zhang received comprehensive training in pharmaceutical sciences, culminating in a doctorate in pharmacy or a related biomedical field (specific degree and institution not provided in the current profile). Her academic journey has been deeply rooted in advancing applied pharmaceutical research, especially in the field of drug delivery and intelligent materials. Her educational background laid the foundation for her specialization in nanoformulations, regenerative medicine, and drug resistance reversal. Professor Zhang has supplemented her academic credentials with continued professional development through her work with major national science foundations and governmental innovation programs. Her commitment to combining traditional pharmaceutical training with cutting-edge material science has enabled her to become a leader in translational research. Although the detailed degrees and institutions are not specified, her track record in high-impact research, publications, and academic leadership reflects a strong and diverse educational background.

🧪 Experience:

Professor Zhang brings over two decades of experience in pharmaceutical sciences, nanomedicine, and biomaterial engineering. She has served in multiple leadership roles, including Director of both the Shandong Engineering Research Center for Intelligent Materials and Regenerative Medicine and the Pharmaceutical Experimental Teaching Center at Shandong Second Medical University. As Principal Investigator on numerous high-profile projects funded by the National Natural Science Foundation of China and regional innovation programs, she has demonstrated excellence in both basic and translational research. Her industrial collaborations and consultancy projects, such as those with NOIMAIER Medical Technology, reflect her ability to translate scientific innovation into practical solutions. Her experience is also reflected in her active editorial and peer review contributions to top-tier journals, as well as her involvement in educational contributions through national textbook projects. Her academic, industrial, and clinical translational experiences make her a uniquely qualified and impactful researcher.

🔬 Research Focus:

Professor Weifen Zhang’s research is at the forefront of targeted drug delivery, intelligent biomaterials, and regenerative medicine. Her primary scientific focus involves developing novel nanoparticle-based platforms to improve therapeutic outcomes in diseases such as non-small cell lung cancer. She has led pioneering studies in dual-drug synergistic delivery, utilizing agents like quercetin and paclitaxel, aimed at overcoming drug resistance. Her lab also explores smart, biodegradable materials, such as Bletilla striata polysaccharide microneedles, for innovative therapeutic applications including hair regrowth and skin regeneration. In regenerative medicine, she is advancing bionic materials, such as mineralized collagen scaffolds, for orthopedic and dental use. Additionally, she works on plant-derived compounds, contributing to both pharmaceutical and agricultural solutions. Through interdisciplinary approaches, including nanotechnology, immunology, and pharmacokinetics, Professor Zhang’s work is positioned to influence both academic research and clinical practice. Her vision continues to shape the field of personalized and precision medicine.

📚 Publications Top Notes:

  1. 📌 Bletilla striata polysaccharide-based dissolving microneedle patch integrated with nanoparticles for promoting hair regrowth

  2. 🧱 Composite scaffolds based on egg membrane and eggshell-derived inorganic particles promote soft and hard tissue repair

  3. 💉 Efficient chemo-immunotherapy leveraging minimalist electrostatic complex nanoparticle as “in situ” vaccine integrated tumor ICD and immunoagonist

  4. 🌿 A Chinese drug-compatibility-based approach to purslane hydrogels for acute eczema therapy

  5. 🔬 Dynamic Covalent Bond-Based Nanoassembly of Curcumin to Enhance the Selective Photothermal Therapy for Tumor Treatment

  6. 🧵 Multifunctional Nanofiber Membranes Constructed by Microfluidic Blow-Spinning to Inhibit Scar Formation at Early Intervention Stage

  7. 📄 Corrigendum to “Synergistically enhanced cancer immunotherapy by combining protamine-based nanovaccine with PD-L1 gene silence nanoparticle”

  8. 💉 Minimalist “in situ” tumor vaccine leveraging versatile dendrimer nanoplatform coordinated ICD and immunoagonist for boosted chemoimmunotherapy

  9. 🧬 A minimalist cancer cell membrane-shielded biomimetic nanoparticle for nasopharyngeal carcinoma active-targeting therapy

  10. ⚗️ Biodegradable Manganese-Containing Mesoporous Silica Nanoparticles for Precisely Controlled Quercetin Delivery

 

📌 Conclusion:

Professor Weifen Zhang demonstrates exceptional qualifications for the Best Researcher Award. Her deep scientific contributions, robust patent portfolio, influential publications, and national leadership in pharmaceutical innovation mark her as a leader in biomedical research. With a few enhancements in global visibility and science communication, her already impressive profile could reach even greater heights.